Here is my brief for why I bought the following growth counters of my portfolio. Click here to read why I buy my income counters.
| Counter | Position | Reason for buying | First bought | Avg. Price* |
| Raffles Medical Group | 3.5% | Expansion of Raffles Hospital locally and China. Cash generating despite expansion. | May 2016 | $1.15 |
| iFAST | 3.3% | An all-in-one financial services. Increasing recurring revenue. Good track record of executing its plan. Big potential China market. | Sep 2017 | $0.93 |
| Food Empire | 2.5% | Established leader for instant coffee in Russia/Ukraine. Successful diversification to Vietnam and potential growth for ingredient segment. | Mar 2018 | $0.64 |
| SaaS | 4.9% | A mini-fund of SaaS companies that have good growth potential in the coming decade. | Feb 2020 | – |
| MFRS2020 | 4.0% | Micro-cap recommendations from Motley Fool. Most companies have market cap of less than US$5 bil. The service aims to double the portfolio in 5 years. | Dec 2019 | – |
| Arista Networks | 4.0% | Disruptor to CISCO and gaining market shares for network. Strong management team and will benefit from increasing usage of cloud services | May 2018 | $240.36 |
| Intuitive Surgical | 3.5% | Leader in robotic surgery and should be able to continue to grow with huge market. | Nov 2019 | $536.63 |
| Ulta Beauty | 3.4% | Reacted to disruption and developed omni-channel to grow its business. Strong CEO who should be able to continue to grow the company. | Mar 2018 | $247.18 |
| Apple | 2.9% | Huge customer base for expansion of its services and wearable market, resulting in more recurring revenue. | Dec 2018 | $168.55 |
| Starbucks | 2.9% | Global brand and fast expansion in China market. Collaboration with Nestle provides another source of revenue. | Mar 2018 | $66.71 |
| VISA | 2.5% | Top payment services that have benefitted with the increasing cashless payment. | Sep 2018 | $157.38 |
| The Walt Disney Company | 2.3% | Strong content creator that allows it to monetise in various ways. Disney+ should benefit it in the long term. | Mar 2018 | $117.98 |
| Illumina | 1.9% | Leader in genetic sequencing and should continue to benefit from the increase in use of genetics in healthcare. | Oct 2019 | $309.33 |
| Adobe | 1.8% | Transformation into subscription services of its popular software has increased its recurring revenue. Reaches out to a larger market with a lower pricing. | Nov 2019 | $324.04 |
*This differs from my new portfolio’s price which is based on 31 Dec 2019 closing.
Towards Financial Independence 